mainli in-lin rev though believ
consensu light expens ramp thu
ep expect stock move mainli driven
guidanc amgn/biib
smid highlight gwph asnd
ow pt ep mse slightli
revenu vs con assum due
limit inventori stock expect model potenti mis-
model otezla impact ep consensu due
lower revenu season higher expens
ahead revenu vs con expect management bracket
consensu expect benefit margin better price
environ well continu otezla growth focu area
includ outcom enbrel appeal expect
updat data assum includ potenti file
nsclc key pipelin readout includ bite data solid
tumor tezepelumab phiii data end omecamtiv mecarbil phiii
data otezla mild/moder psoriasi studi advanc
expect signific move quarter guidanc
uw pt ep mse ahead total
revenu vs con driven mainli modest stock like
better ou spinraza revenu versu consensu ep also benefit
sharecount reduct also ahead revenu
vs con driven higher expect across multipl
sclerosi portfolio in-line spinraza expect management may guid use
wide rang given multipl potenti scenario tecfidera ip
focu area includ updat current legal case tecfidera
expect ipr rule district court decis time
aducanumab file potenti panel assum earli potenti
pdufa date assum late impact potenti competitor
ew pt ep mse ahead
revenu vs con driven higher hiv revenu expect
stock due normal cadenc price increas recal last year
management delay price increas late revenu
vs con due lower hiv revenu believ consensu mis-
model destock due truvada gener well switch
descovi prep management indic would achiev convers
believ could face pressur guidanc focu
pleas see price target chang exhibit
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
area includ impact expect car-t drg code april
yescarta well dlbcl yescarta data management next step nash
expect focu patient look forward data easl
shape descovi prep launch curv management indic
truvada patient alreadi switch chang management capit
alloc strategi current focus small-to-mid size bolt-on
major transform deal
ow pt ep mse line total
revenu slightli consensu revenu
vs con believ taken cautiou approach
eu ramp given recent reimburs agreement overal expect
stock perform dictat trikafta launch expect
beat expect pipelin progress trikafta launch capit alloc
decis major driver focu aatd data
would expect see carrier level protein upsid
surpris function protein protect level base case
busi develop management complet non-aatd pipelin
updat could drive upsid believ risk-adjust aatd
current reflect valuat
announc eylea revenu con expect
littl focu number major focu sanofi jv
restructur previous comment management confirm
restructur accret believ stock perform base
detail expect around earn expect
management provid top-lin guidanc key item focu os
interim nsclc progress bispecif potenti pivot dataset
dlbcl fl management indic fda want orr combin least
month durabl data impact novarti beovu eylea
management continu confid abil maintain market share
ow pt ew pt alexion biomarin either pre-
announc reiter guidanc expect littl debat
gmab gener in-lin consensu
expect in-lin guidanc ahead consensu
revenu vs includ small contribut tucatinib
us assum robust ramp padcev given multipl new
launch unsur management may choos guid includ
recent pre-announc epidiolex sale strong number
well estim stock preform well sinc
updat last week believ compani could elect provid
guidanc therapi earn report guidanc
would lessen uncertainti regard revenu project epidiolex
also pre-announc top line sale achiev strong
onpattro sale versu estim similarli compani could issu
first time guidanc drug earn announc respect
givlaari earli launch compani pre-announc
modest sale new patient start form expect updat
launch metric asnd expect investor focu primarili upcom
data transcon pth phii path forward trial data
first substant look therapi report close proxim
earn posit data studi could materi impact investor
project regard drug lead upsid model
ew pt ow pt ew pt
 jakafi sale line consensu vs con
addit sale expect investor focu heavili jakafi sale
guidanc sale estim line con also expect
investor look addit color recent announc deal
tafasitamab see initi take upcom phiii readout
ruxolitinib cream atop dermat expect given
management pre-announce tymlo sale expect investor
focu driver guidanc rang management view
potenti forteo competitor enrol updat phiii abalo-
patch studi strateg review process elacestr management
pre-announce andexxa sale see note expect investor
look andexxa sale guidanc management previous note
possibl continu scrutin andexxa use trend drug review
process discuss pre-announce
nc chang price
equal-weight rate base
expect limit upsid near-term
posit luspatercept
assum high probabl approv
preliminari phase part data
preliminari sotatercept data phase
pulsar studi patient pah
data non-transfus depend beta-th
risk achiev price
data better-than-expect luspatercept
downsid risk neg cmt data
luspatercept approv md
pt deriv dcf use
discount rate assum po rs md transfusion-
depend beta-th addit assum po
first line md non-transfusion-depend beta-th mf
posit data mf non-transfus depend beta-th bull case
assum higher probabl success po non-transfus
depend beta-th mf
luspatercept launch reach peak ww revenu
first two indic base case assumpt describ price
target methodolog
luspatercept launch slower-than-expect bear case assum peak
us market share md beta-th respect
addit assum luspatercept success follow-on indic
vadadustat drive akebia share
vadadustat drive akebia share
pt deriv dcf use discount rate
termin growth rate beyond valu akebia nephrolog
vadadustat exce expect allow therapi take addit share
epo regimen appli risk adjust
vadadustat launch drug profil allow success howev
ampl risk remain program lead risk adjust
vadadustat fail compani valu cash
equal-weight ahead phiii
major cardiac event mace data
see vadadustat therapi
benefit allow remov black
box respect cardiovascular event
might necessari success versu
infrastructur auryxia need show us
akebia merg keryx late
join auryxia vadadustat
compani ckd aresen auryxia
underperform sinc approv
hypophosphatemia though drug
recent expand label includ iron
defici anemia need see
drug perform gain confid
main valuat driver
perceiv clinic regulatori risk
vadadustat ckd dialysi set
risk achiev price
akebia upcom mace data unabl
show vadadustat safer esa
would lead substanti weak
auryxia continu under-perform
akebia might need rais addit fund
issu equiti
cost expens
product revenues/royalti
cash equival
prepaid expens current asset
properti equip net
defer revenu net current portion
accumul comprehens incom loss
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
prepaid expens asset
accru expens liabil
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas market secur
sale matur market secur
net use invest activ
flow financ activ
proce exercis stock option equiti
proce issuanc common stock
chang equival
equival begin year
chang due restat
equival end year
market secur restrict end year
safeti efficaci data ftd-grn drive risk/reward
safeti efficaci data ftd-grn
pt deriv dcf use discount
rate termin growth rate revenu driver model
current model
separ given earli stage develop
commerci strong uptak bull
case valu product launch
begin respect gener
sale
success commerci base
case valu product launch
begin respect gener
risk-adjust sale
fail unabl commerci trade cash
overweight thesi base
success commerci
design treat well defin
genet diseas measur biomark
compar neurodegen
probabl success
phi trial healthi volunt
demonstr target engag
provid confid impact genet
infront phii data ftd-pgrn
patient expect
phi pom data alzheim diseas
patient expect
risk achiev price
signal would like caus investor
question valu
reduc efficaci ftd
delay timelin posit data
competitor could weigh
market share especi competitor data
arriv new indic prior pivot
effect treat
ultomiri share convers soliris/strensiq/kanuma sale growth drive
ultomiri share convers soliris/strensiq/kanuma sale growth drive
equal-weight believ
current valuat impli manag
unabl grow busi
overlook share shift potenti
ultomiri even conserv scenario
assum ultomiri achiev solid
profil assum either market share
price pressur year
assum strensiq achiev
meaning sale see modest sale
key revenu driver model
continu ahu pnh sale growth
franchis coupl growth
soliri mg success share shift
risk achiev price
soliri pnh ahu mg growth could fail
meet expect
strensiq and/or kanuma fail captur
share convers soliri ultomiri
project
could potenti bad
behavior identifi commerci
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model pnh sale ahu sale mg sale nmo sale strensiq
sale kanuma sale incorpor cash cost stock
diagnost algorithm drive sustain pnh ahu mg penetr
ultomiri succe signific share convers bull case assum
soliri becom standard care pnh ahu nmo mg pnh
sale peak ww ahu sale peak
assum strensiq kanuma continu launch sale
respect
soliri meaning growth pnh ahu gmg ultomiri succe
modest share convers base case assum solid convers ultomiri
long-term durabl complement franchis assum gmg
nmo meaning contribut sale assum strensiq kanuma
continu launch sale respect
see soliri longev incorpor competit price pressur
soliri face signific competit strensiq kanuma achiev minim
sale bear case assum soliri fail gain label expans soliri
face signific headwind biosimilar proprietari competit
diversif strensiq kanuma minim
recent approv drug advanc pipelin drive valu
 advanc pipelin drive valu
pt deriv dcf use discount rate
termin growth rate beyond valu alnylam advanc
attr platform highli success givlaari lumasiran achiev strong sale
fitusiran inclisiran launch bull scenario assum onpattro
follow-on highli success form attr
givlaari lumasiran launch sell well fitusiran inclisiran
abl success gain approv appli modest pipelin valu
drug includ cemdisiran
attr franchis drive valu givlaari launch lumasiran launch
onpattro strong launch attr la launch aln-
drive sale model aip revenu givlaari
begin lumasiran launch risk adjust
incorpor royalti inclisiran appli modest pipelin valu
onpattro continu modest sale givlaari grow slowli
overweight alnylam
believ mani risk challeng
alnylam give way
commerci growth expect
investor focu onpattro launch
exceed expect view
expect givlaari launch
lumasiran
view alnylam rnai platform
high potenti valu consid
rnai simpler demonstr
preclin proof concept
technolog alnylam larg pipelin
beyond ttr therapi offer potenti
substanti downstream valu
continu ramp onpattro
initi ramp givlaari well
clinical/regulatori updat lumasiran
inclisiran fitusiran
risk achiev price
pipelin failur proprietari
rnai therapi could lead substanti
chang share valu
neg safeti and/or efficaci data
therapeut program
clinic data competit program
suggest disadvantag drug
million per share basi indic
net revenu collabor
cost expens
product revenu royalti
million per share basi indic
equival
prepaid expens current asset
properti equip net
defer revenu net current portion
total liabil sharehold equiti
million per share basi indic
adjust reconcil net loss net cash use oper activ
depreci amort
chang oper asset liabil
pre-paid expens asset
accru expens
purchas properti plant equip
purchas market secur
sale matur market secur
increas reduct restrict
payment asset acquisit
net use invest activ
proce exercis stock option equiti
proce issuanc common stock
proce issuanc debt
net provid financ activ
chang equival
equival begin year
equival end year
market secur end year
biosimilar competit pipelin contribut drive risk-reward
biosimilar competit pipelin contribut drive risk-reward
overweight amgen believ
upsid pipelin recent
launch help reduc long-term risk
compani current base busi face
signific in-organ opportun growth
stabl base even biosimilar
believ protect key franchis
biosimilar competit near-term
long-term forecast gradual share
shift biosimilar versu cliff key
product neulasta enbrel
project period
divers pipelin begin
appreci gener posit
late-stag data key pipelin compound
earli aimovig launch migrain
appear encourag also
develop portfolio biosimilar
molecul believ take share
also watch matur
certain early-stag oncolog program
shown progress recent month
support global expans commerci
continu launch perform aimovig
erenumab migrain approv launch
biosimilar molecul
advanc early-stag
biosimilar entrant key legaci product
enbrel neulasta enbrel price power
potenti launch pipelin product
tezepelumab
risk achiev price
failur late-stag pipelin
lack margin expans
deriv pt discount cash flow dcf analysi
use wacc termin growth rate post
bear case main revenu driver model
eros base busi due biosimilar matur
lower biosimilar impact coupl outsiz revenu pipelin
assum pipelin sale tezepelumab peak
biosimilar revenu aimovig sale
sale modest line penetr
kyproli peak sale enbrel long-term patent hold
biosimilar enter market minim impact biosimilar
expos product biosimilar neulasta take total neulasta share
us biosimilar impact similar trend europ modest result
pipelin assum pipelin sale tezepelumab
peak biosimilar revenu aimovig sale
sale modest line
penetr kyproli peak sale enbrel
biosimilar start take share modest impact biosimilar
expos product biosimilar neulasta take total neulasta share
assum assum pipelin failur tezepelumab
line penetr kyproli relapsed/refractori market
peak sale declin y/i thereaft notabl impact biosimilar
expos product biosimilar neulasta take total neulasta share
biosimilar take total share
aimovig fail achiev signific market share migrain market
pt deriv discount cash flow analysi assum
discount rate termin growth valu assum peak us
market share md md
post-transpl mainten mutant aml
adjust use probabl success po
higher po md assum higher po md mds/aml
post-transpl mainten r/r aml follow posit data
base case assumpt describ price target methodolog
platform reactiv mutant fail aprea unabl advanc
product candid trade cash value-per-share
equal-weight aprea
develop cancer therapi reactiv
mutant posit
compani believ share fulli
valu follow strong perform
sinc ipo result remain
sidelin look better entri point
ahead phase data
date phase data two studi
indic improv respons rate apr-
azacitidin histor azacitidin
md aml patient
compani focus initi md
aml evid
could effect treat solid tumor
upcom catalyst
final data french phase
initi data phase studi
r/r aml
top-lin data phase md
risk achiev price
lack statist signific improv
azacitidin azacitidin
phase md
lack advanc early-stag
potenti litig patent
competit mds/aml
safeti efficaci data mg itp pv drive risk/reward
safeti efficaci data mg itp pv
pt deriv dcf use
discount rate termin growth rate revenu driver
model
commerci strong uptak bull case
valu risk adjust vari
product launch begin
respect gener sale
argenx success commerci base
case valu mg itp pv aml ctcl risk adjust vari
product launch begin
respect gener sale
fail argenx unabl commerci argx trade
overweight thesi base
success commerci
sever compani develop anti-
fcrn antibodi treatment
autoimmun diseas mani compani
report safeti and/or reduc efficaci
compar
design uniqu ph-
depend bind profil extend
therapeut durabl fewer report
advers event compar compet anti-
diseas indic demonstr
efficaci safeti
demonstr clinic
activ aml
phiii data gmg demonstr
differenti safeti efficaci
phii data pv itp also
top-line phiii data gmg expect
demonstr efficaci aml
risk achiev price
signal would like caus investor
question differenti valu
reduc efficaci
delay timelin posit data
competitor could weight
market share especi competitor data
arriv new indic prior pivot
effect treat
refractori aml patient compar
standard care
transcon hgh launch primari near-term opportun pipelin drive
launch primari near-term opportun pipelin drive
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model transcon hgh pth
deeper penetr transcon hgh pth cnp rapid adopt
transcon commerci product driven differenti risk-benefit profil
trancon hgh strong grower current project launch
therapi risk-adjust revenu reach assign
risk adjust given posit phiii data date pediatr larg drive
valuat predict drug gain use adult assum
transcon pth would launch
transcon pth fail launch hgh modest penetr clinic
failur result revenu pth hgh gain modest
transcon hgh could game changer
growth hormon market drug like
approv growth hormon defici
data date show posit result
two phiii studi nave height
trial pre-treat flight trial patient
bla transcon hgh track
submit long act hgh
welcom addit prescrib
patient allow ascendi
prescript ramp quickli project
opportun transcon pth replac
therapi treatment
hypoparathyroid could potenti
establish infusion-lik profil
long-act mechan incorpor
transcon technolog allow drug
address root caus diseas
current model launch transcon
manag note potenti
expand growth disord
provid opportun leverag
potenti synergi within platform plan
also made move oncolog
overal mechan combin benefit
prodrug predict releas
technolog model launch
primari driver ascendi
success pipelin candid increas
investor confid transcon platform
contribut greater overal valu
risk achiev price
clinic failur transcon pth
due lack efficaci emerg safeti
investor lose confid platform
cost expens
product revenues/royalti
revenu
net loss attribut common stockhold
oper expens
cash equival
properti equip net
invest associ
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
revers non-cash consider regard revenu
revers share profit/ loss associ
revers financ incom
revers financ expens
revers tax charg
chang oper asset liabil
flow gener from/ use oper
net provid use oper activ
flow invest activ
acquisit properti plant equip
net use invest activ
flow financ activ
proce exercis stock option equiti
capit increas
proce lt debt
effect fx translat
chang equival
equival begin year
equival end year
attract lentivir gene therapi platform drive valu
attract lentivir gene therapi platform drive valu
gene therapi compani
develop lentivir therapi lysosom
compani lead therapi
fabri diseas alreadi clinic data
human suggest therapi
could potenti cur derisk
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model risk adjust sale fabri diseas gaucher
diseas market well underli gene therapi platform valu
steeper ramp fabri gaucher scenario assum first revenu avr-rd-
reach peak appli risk adjust
launch reach peak risk
adjust includ modest peak adjust sale pomp cystinosi
fabri gaucher drive valu scenario assum first revenu
reach peak appli risk adjust avr-rd-
launch reach peak risk adjust
program fail valu cash
establish market alreadi identifi
popul also regulatori path well
establish make diseas less riski
rare diseas opportun
program earliest
potenti approv primari driver
valuat gaucher
diseas also key driver
risk achiev price
poor clinic data neg impact
street view specif pipelin
product gene therapi whole would
detriment share valu
lsd establish market
standard care product
like higher bar success
compet technolog gene
competit risk long haul
cost expens
good sold
net incom common sharehold
prepaid expens current asset
properti equip net
defer revenu net current p\ortion
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
prepaid expens asset
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas market secur
sale matur market secur
net use invest activ
flow financ activ
proce exercis stock option equiti
proce issuanc common stock
effect exchang rate
chang equival
equival begin year
equival end year
market secur end year
success develop intern oncolog therapi access global market
success develop intern oncolog therapi access global market
success acquir oper multipl partnership local china
success acquir oper multipl partnership local china
pt deriv dcf use discount rate
termin growth rate beyond valu beigen four clinic
stage product candid recent acquir oper china
beigen four product candid achiev strong uptak china
ex-china market driven differenti profil uniqu
combin therapi product sale reach
beigen
earn royalti ex-china sale celgen china
portfolio gener annual sale amgen china oncolog
portfolio gener annual sale
beigen abl launch four current clinic stage product
candid modest uptak within outsid china product sale
estim
beigen earn royalti ex-
china sale celgen china portfolio gener
annual sale amgen china oncolog portfolio gener
annual sale
failur develop launch molecul combin
therapi china ex-china market
overweight beigen preclin
earli clinic data indic beigen four
parp inhibitor could
present differenti profil varieti
beigen uniqu posit develop
i/o combin therapi given own
compon drug preclin studi in-
hous combin promis date
choos develop drug china
beigen elig pursu potenti
acceler path approv
multi-national competitor could provid
year head start access chines
uptak oncolog drug china
indic strong demand healthcar
insur reform grow market
time believ chines market
could serv valuat backstop
beigen partnership celgen
other provid commerci
portfolio china provid
infrastructur help facilit eventu
commerci beigen product
candid china
updat global penetr btk
parp program
develop commerci
multipl portfolio partnership china
risk achiev price
on-going clinic trial particularli
beigen therapi tislelizumab nsclc
zanubrutimab cll
inabl demonstr superior
compet compound later-stag
regulatori chang china
develop posit access
inabl penetr chines
market enter nrdl
spinraza tecfidera ocrevu pipelin drive risk-reward
spinraza tecfidera ocrevu pipelin drive risk-reward
ocrevu pipelin
tecfidera reach higher market share limit impact biosimilar
signific margin expans lower discount pipelin asset
assum peak tecfidera sale gener
limit declin plegridy/avonex franchis
continu tysabri growth peak sale aducanumab
sale spinraza sale limit
impact rituxan/gazyva biosimilar
impact assum peak tecfidera sale gener
enter declin plegridy/avonex sale
stabl tysabri sale aducanumab
sale biosimilar rituxan impact start mainli
off-set grow ocrevu royalti
impact pipelin assum global tecfidera sale
loss patent protect declin plegridy/avonex sale
greater competit signific neg price
environ biosimilar rituxan impact start
uw rate base view
risk base busi weigh
spinraza competit potenti
rituxan biosimilar overhang
tecfidera ipr expect
management track record transform
late-stag limit
expect signific capit
management chang strategi
aducanumab approv
risk achiev price
faster expect launch new
rimegep competitor migrain data glutam platform valid drive
rimegep competitor migrain data glutam platform valid drive
deriv pt discount cash flow dcf analysi
assum wacc termin growth rate post
main revenu driver model rimegep
episod migrain lesser extent glutam platform
robust rimegep uptak episod migrain commerci
chronic migrain strong share addit neurolog indic
glutam platform net product sale driven sale
rimegep aggreg cgrp
platform ex-u sale aggreg sale trigriluzol bhv-
 ex-u
strong share rimegep episod migrain modest share
addit neurolog indic glutam platform
product sale driven sale rimegep
ex-u commerci commerci chronic
migrain aggreg sale trigriluzol
 commerci ex-u
pipelin failur rimegep glutam platform molecul fail
develop process compani trade cash value-per-share
equal-weight biohaven lead
larg unmet need acut treatment
migrain phiii data suggest product
could differenti emerg
competitor particularli safeti howev
believ valuat reflect posit
aspect thu see balanc
signific pipelin driver troriluzol bhv-
gener encourag
data troriluzol achiev
statist signific result phii/iii
spinocerebellar ataxia sca program
result drug inabl differenti
placebo seem trial/ind specif
current see limit read
glutam program expect key
data glutam platform
rimegep pfuda acut
phiii rimegep data prevent
treatment migrain
glutam data particularli troriluzol
gad
risk achiev price
regulatori hurdl rimegep
poor safety/efficaci data
base busi brineura vosoritid bmn drive valu
base busi brineura vosoritid bmn drive valu
aldurazym pipelin vosoritid bmn greatest
extra strength pipelin assum expect growth base
busi drug pipelin vosoritid bmn becom even larger
driver valu
pipelin contribut assum base busi perform well come
year also pegvalias approv trifecta vosoritid bmn
 bmn launch model bmn
bmn
pipelin current approv drug assum drug
pipelin unabl gener satisfactori result gain market approv
bear scenario
leader orphan opportun biomarin
uniqu player core
compet orphan drug set apart
larg cap emphas market
target larger popul
strength base busi establish
valu base busi vimizin naglazym
kuvan aldurzym contribut
revenu given natur market outsid
competit unlik allow base
busi creat valuat backstop
deep pipelin offer plenti
opportun upsid biomarin deep
wide product pipelin multipl drug
potenti launch end
vosoritid bmn possibl
blockbust contribut upsid
pipelin opportun near-term focu
investor focu pipelin
opportun nearer-term launch
pegvalias pku well potenti
blockbust vosoritid achondroplasia
valrox gene therapi treatment
find patient drive sale
base busi base busi drug
still grow recent launch
vimizim still leg drive sale
biomarin abil steadili find new patient
grow revenu opportun
bmn hemophilia gene therapi
bmn could signific impact
valuat matur data becom
risk achiev price
neg updat key pipelin drug
highlight safeti efficaci risk
bmn failur phase
focu orphan asset price could
impact investor view base busi
pipelin upsid particularli impact
termin valu busi
expens manag particular
meet year oper margin target
car-t bcma sickl cell beta-thalassemia gene therapi drive risk/reward
car-t bcma sickl cell beta-thalassemia gene therapi drive risk/reward
signific sickl cell uptak bcma car-t high share relaps set
modest beta-thalassemia penetr assum larg portion
elig scd patient receiv gene therapi signific portion
new incid popul receiv therapi beta-thalassemia assum
row penetr assum strong launch penetr
front line patient
uptak beta-thalassemia us/eu strong bcma car-t uptak
line moder sickl cell penetr scd project peak ww sale
assum oral competit baselin factor organ damag
stroke etc may limit uptak gene therapi beta-thalassemia
assum penetr develop market scd price
lentiglobin fail make market assum scd
beta thal make market model cash-bas valu assum
launch
equal-weight
compani progress sickl cell diseas
reflect valuat see car-t
bcma program main upsid
believ initi data repres
proof-of-concept allow us valu
penetr sickl cell market
penetr beta-thalassemia
see initi bcma car-t data
strong highli valu segment
peak sale assum
maintain major share
competit compani
addit car-t data durabl
data earlier line therapi
addit data follow-up
lentiglobin beta-th scd studi
new clinic program either gene
therapi car-t gene edit
risk achiev price
potenti efficaci safeti concern
would inhibit manag team
bring market addit
indic earlier line
efficaci lentiglobin given
limit number patient potenti
variabl patient engraft diseas
sever patient respons
safeti lentiglobin given lack
long-term follow-up limit patient
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model avapritinib pralsitinib
deeper penetr avapritinib assum deeper penetr avapritinib
line therapi kit driven gist form sm well
pralsetinib
avapritinib ramp assum avapritinib launch pdgfr
resist gist kit gist kit driven gist project
launch pralsetinib appli risk
assum avapritinib use pdgfr resist gist popul
avapritinib indic pralsetinib unapprov
avapritinib key valu driver
blueprint drug approv
pdgfra exon mutant gist
approv fourth-lin gist
gist potenti systemat
pralsetinib appear promis though
competit dynam could well impact
therapi long-term prospect earli data
pralsetinib show tki highli
repres
underappreci opportun
diseas rel treatment
option current avail drug
fairli ineffect poorli toler
blueprint present earli dose rang
data show promis efficaci
primari driver blueprint
avapritinib kit pdgfr mutant gist
well sm
risk achiev price
clinic failur avapritinib pralsetinib
due lack efficaci emerg
earlier stage pipelin fail advanc
collabor yield viabl
cost expens
product revenues/royalti
net incom loss continu oper
cumul dividend convert prefer share
net loss attribut common stockhold
oper expens
cash equival
prepaid expens current asset
properti equip net
current portion defer revenu
accru expens current liabil
accumul comprehens incom loss
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas short-term invest
matur short-term invest
net use invest activ
flow financ activ
proce issuanc common stock
net proce issuanc convert prefer stock
proce lt debt
effect fx translat
chang equival
equival begin year
equival end year
market secur end year
efficaci phase studi drive risk/reward
efficaci phase studi drive risk/reward
pt deriv discount cash flow analysi assum
discount rate termin growth valu estim us/eu
risk-adjust peak revenu use
po mucos pv/mucocutan pv/musk mg
receiv acceler fda approv
respect similar therapi kymriah estim us/eu risk-adjust
peak revenu
program approv full phiii program musk-
caart receiv tradit fda approv
respect estim us/eu risk-adjust peak revenu
fail fail receiv regulatori approv impact
overal caart platform viabil trade cash value-per-share
believ cabaletta proprietari
platform yield analog efficaci
compar therapi circumv
believ promis
compound demonstr
favor efficaci safeti profil
preclin studi see upsid
potenti acceler approv phi
believ manag continu
identifi auto-immun diseas
caart technolog appli
demonstr favor safeti profil
low rate expect
vivo target engag confirm
preclin studi musk-caart
move compound clinic test
earli
demonstr favor efficaci profil
effici specif cell targeting/kil
expect
risk achiev price
question valu
overal platform
unexpect safeti signal
caart trial would like caus investor
regul question risk-benefit ratio
lower probabl success
delay timelin posit data
pt deriv dcf use
sale adjust revenu use probabl
success po om reldesemtiv al
reldesemtiv sma
greater market share bull case assum greater adopt
omecamtiv mecarbil reldesemtiv
om commerci begin base case assumpt
describ price target methodolog
product candid fail advanc unabl advanc
product candid trade cash value-per-share
equal-weight thesi base lack
signific clinic catalyst ahead
omecamtiv mecarbil phase data
cautiou reldesemtiv given data
sma al
efficaci galactic-hf
omecamtiv mecarbil phase data
risk achiev price
data omecamtiv mecarbil
stop interim overwhelmingli
posit efficaci faster-than-expect
advanc pipelin candid
phase data galactic-hf
termin earli futil follow
step viaskin peanut program drive risk/reward
step viaskin peanut program drive risk/reward
deriv pt dcf base forecast dbv peanut
rate termin growth rate
modest share viaskin peanut commerci viaskin milk
viaskin egg viaskin peanut launch late gener peak ww sale
viaskin milk viaskin egg launch
respect obtain minim share achiev global
sale
modest uptak viaskin peanut commerci viaskin milk
viaskin egg viaskin peanut launch late gener
global sale contribut viaskin milk viaskin egg
given current regulatori statu viaskin peanut assum
probabl success
regulatori failur viaskin peanut commerci viaskin milk
and/or viaskin egg share trade cash value-per-share
equal-weight
gener mix phiii top line profil
manag subsequ pull back
bla viaskin peanut follow issu
highlight fda bla
resubmit accept fda
review believ regulatori progress
viaskin peanut bla particularli
repres next key step dbvt
anticip advisori committe meet
discuss viaskin peanut bla
regulatori action competitor peanut
allergi product candid anticip
risk achiev price
lack support viaskin peanut
anticip fda advisori committe
greater expect competit
dbv nsdq dbvt million
cost expens
sale
research develop
sell gener administr
non- adjust
research develop
gener administr
st invest
cash equival
inventori work progress
custom account receiv relat receiv
properti equip net
supplier account payabl relat payabl
premium relat share capit
total liabil stockhold equiti
adjust reconcil net loss net cash use oper activ
depreci amort
expens relat share-bas payment
chang oper asset liabil
inventori work progress
net cash use oper activ
acquisit properti plant equip
acquisit intang asset
acquisit non-curr financi asset
cash flow relat invest transact
net cash use invest activ
increas condit advanc
decreas condit advanc
capit increas net transact cost
cash flow relat financ activ
net cash provid financ activ
effect exchang rate chang cash cash equival
net decreas increas cash cash equival
cash equival begin period
cash equival end period
program al alzheim parkinson bbb platform drive risk/reward
program al alzheim parkinson bbb platform drive risk/reward
pt base dcf base case forecast
parkinson al alzheim bbb platform
discount rate assum termin growth cash
greater alzheim market share success idiopath parkinson
bull case assum market share al market share
alzheim share total parkinson popul alzheim
risk-adjust us peak sale program
program
risk-adjust success alzheim good probabl success
mutat valu bbb program base case assum
market share al market share alzheim share
mutat parkinson us peak risk-adjust sale
program program bbb program repres
total peak revenu
alzheim success mutat parkinson valu bbb
program approv al alzheim approv
parkinson al program gener peak revenu
program gener peak revenu bbb program repres
peak revenu
overweight thesi base
confid manag abil
inflect product histor
difficult treat area neurosci
believ manag right
process inflect success use
genet target biomark target
engag parallel invest
improv success initi target
repres initi yardstick
opportun greatli expand treatment
engag inhibitor
engag data patient
program
potenti evid activ idiopath
initi preclin clinic data
demonstr util bbb
risk achiev price
preclin clinic safeti signal
program
inabl advanc
program clinic test due poor
efficaci concern safeti signal
failur bbb program greater
success competitor similar program
demonstr safe administr human ip resolut success
demonstr safe administr human ip resolut success
pt deriv dcf use discount rate
edita abl develop commerci therapi receiv widespread
uptak therapi launch us eu treat
cure address popul command premium
price gener peak ww sale edita also abl
realiz sale addit therapi car-t applic
non-malign hematolog dmd cf
therapi prove success addit therapi obtain modest
success therapi launch us eu treat
cure address popul gener peak ww
sale edita abl develop success therapi car-
hematolog dmd cf achiev sale
pipelin program fail edita abl commerci therapi
result valuat cash share
equal-weight
crispr gene edit platform
derisk oper standpoint
gear toward numer diseas
target howev deliveri long-term
safeti administ clinic relev
dose human need proven
edita system modular approach
may allow differenti
first diseas target
inherit retin dystrophi lower initi
risk prove gene edit work
human eye immun privileg
provid small contain area
suffici quantiti vector
overal see signific long-term
potenti edita remain equal-weight
initi therapi derisk clinic
progress program
program clinic
hematolog diseas genet diseas
lung liver
risk achiev price
ip outcom limit edita freedom
develop risk associ earli
natur pipelin timelin long
competitor could influenc investor
percept stock
pt deriv dcf use discount rate
termin growth rate beyond valu tazemetostat
tazemetostat approv ramp well assum tazemetostat launch es
fl strong uptak line therapi
tazemetostat launch strength later line assum tazemetostat
launch es fl assum bulk usag fl come
later line therapi
program fail compani valu cash
tazemetostat promis therapi
like approv epitheliod
sarcoma es earli follicular
lymphoma fl end year
drug broad applic
hematolog cancer potenti
applic solid tumor well
primari near term driver
regulatori clinic updat
tazemetostat fl well like earli
fda approv launch es
risk achiev price
safeti issu previous
concern abat addit episod
could caus bubbl surfac
place pressur share
might suffici efficaci
compet current treatment
collabor fail result meaning
cost expens
product revenues/royalti
oper expens
equival
prepaid expens current asset
properti equip net
current portion defer revenu
accru expens current liabil
current portion capit leas oblig
capit leas oblig net current portion
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas short-term invest
proce sale short-term invest
net use invest activ
flow financ activ
proce public offer common stock net commiss
proce stock option exercis
issuanc share employe stock purchas plan
net proce issuanc convert prefer stock
proce lt debt
payment capit leas oblig
payment common stock offer cost
chang equival
equival begin year
equival end year
market secur end year
probabl success monoclon microbi therapi drive risk/reward
probabl success monoclon microbi therapi drive risk/reward
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model evelo lead monoclon microbi product candid
atop dermat psoriasi
signific share atop dermat psoriasi evelo inflamm
focus monoclon microbi launch atop dermat
psoriasi atop dermat evelo product gain share peak
patient control topic treatment psoriasi evelo obtain
share peak patient biolog oral respect assum
probabl success po atop dermat po psoriasi
estim peak pos-adjust revenu
modest share atop dermat psoriasi evelo product candid gain
share peak atop dermat patient control
topic treatment gain share peak psoriasi
patient biolog oral respect estim peak pos-adjust
revenu
program fail valu compani cash
treat system condit via gut-
bodi network nascent field evelo
signific clinic literatur recent
year support premis gut-bodi
network preclin data gener
date evelo lead product candid
inflamm oncolog encourag
initi phi data report recent lead
product candid demonstr
encourag efficaci signal psoriasi
scalabl sever potenti target
therapeut inher safe
deriv gut
phi data atop dermat
phi data atop dermat
phi/ii data oncolog
indic
phii interim data
psoriasi late
risk achiev price
earli setback microbiom
focus compani may weigh investor
futur readout replic
efficaci signal observ initi phi
unforeseen safeti signal
upcom
pt deriv dcf use discount
rate model peak us market share translat
peak sale rcc assum peak us market share
translat peak sale
greater peak market share rcc bull case assum
peak us market share translat peak sale
addit assum peak us market share rcc share
translat peak sale rcc
expect gradual launch base case assumpt
describ price target methodolog
lower long-term market share rcc greater-than-expect
competit pressur beyond cabozantinib market share declin
patent expir rcc reach share rcc
equal-weight believ
posit expect cabozantinib
rcc larg price share
limit clinic catalyst ahead
checkmat data earli
believ sale growth
gradual
phase data rcc
phase data
phase data dtc
risk achiev price
cabozantinib earlier stage trial
posit expect new later
stage asset program announc
addit data report support
advanc cabozantinib indic
beyond rcc
slowli expect combin
studi cabozantinib earlier stage
trial succeed
updat antibodi magrolimab drive risk/reward
updat antibodi magrolimab drive risk/reward
pt base dcf use discount rate project free
cash flow base termin valu
onward use termin growth rate project revenu
lead product candid md dlbcl risk-adjust
strong uptak md dlbcl success mutant aml
see strong uptak use broadli across r/r front line
dlbcl set base case gener peak risk-adjust sale
gain greater share higher-risk share lower-
risk md gener peak risk-adjust sale also
gain moder share mutant aml gener peak risk-adjust
sale
modest uptak md dlbcl dlbcl gener risk-
adjust revenu md
gener risk-adjust revenu
assign po probabl success dlbcl md
fail tumor type fail develop stage across
indic result forti seven trade cash value-per-share
overweight forti seven
believ earli clinic data gener
antibodi highli encourag across
oncolog indic could first-in-
class therapi new categori checkpoint
data gener date indic
potenti strong singl agent activ
well activ could complementari
anti-canc agent
progress toward us pivot phiii studi
phib/ii pivot data respons
durabl azacitidin md
phi data studi avelumab
ovarian cancer
phi data studi cetuximab
colorect cancer
risk achiev price
poor efficaci and/or safeti data lead
stronger expect data
losmapimod efficaci phase ii studi drive risk/reward
efficaci phase ii studi drive risk/reward
pt deriv discount cash flow analysi assum
discount rate termin growth valu assum peak
impli us market share fshd adjust use
probabl success po
losmapimod receiv acceler approv phiib data biomark
earli clinic data suffici acceler approv losmapimod
preclin program advanc earli clinic studi
losmapimod approv full phiii program losmapimod meet
primari endpoint phase ii thu demonstr potenti treat fshd
fda requir full clinic program long-term follow-up fshd
patient scenario fulcrum requir conduct phase studi
losmapimod fail losmapimod fail receiv regulatori approv
trade cash value-per-share
believ fulcrum proprietari
target discoveri platform yield
import small molecul target genet
believ losmapimod promis
compound demonstr target
engag fshd higher
typic phiib probabl success clinic
studi see upsid potenti
acceler approv data
believ manag continu
find genet target exploit
small molecul see potenti
target engag muscl expect
studi data demonstr efficaci fshd
patient expect
demonstr efficaci fshd patient
expect
risk achiev price
question valu losmapimod
caus investor regul disregard
avail safeti data gsk prolong
timelin lower probabl
delay timelin posit data
filgotinib ra ibd pipelin asset drive risk/reward
filgotinib ra ibd pipelin asset drive risk/reward
deriv pt discount cash flow analysi use
wacc cash flow forecast expir
filgotinib patent main driver filgotinib
filgotinib still major driver assum greater share ra ipf
oa pipelin asset gener signific sale assum po
adjust peak sale filgotinib ra uc
cd total filgotinib mileston payment
ipf gener peak po adjust global sale
oa gener peak po adjust global sale
filgotinib drive forecast strong contribut ipf oa
pipelin asset assum po adjust peak sale filgotinib
ra uc cd
total filgotinib mileston payment ipf gener
peak po adjust global sale oa gener
peak po adjust global sale
filgotinib pipelin asset fail manag continu invest
 assum cash-per-share valu
overweight galapago
believ filgotinib addit pipelin
asset differenti carv
market share competit
filgotinib differenti profil versu
oral competitor xeljanz
olumi believ best class
efficaci cleaner safeti profil
especi anemia across indic
model peak po adjust global sale
filgotinib
filgotinib potenti approv
key inflammatori indic beyond
rheumatoid arthriti includ crohn
spondyl psoriat arthriti
data pipelin asset
ipf oa
encourag enough us incorpor
probabl adjust estim
molecul valuat await
main driver advanc
filgotinib ra ibd along continu
progress ipf oa program
risk achiev price
take signific time phase ii safeti
profil may assur protect
unknown side-effect broader phase
approv risk regulatori approv
assur potenti failur
gain approv one geographi
commerci risk ra market
competit number market
agent along agent develop
filgotinib pipelin product may
durat hcv sale hiv patent expir car-t/pipelin drive risk-reward
durat hcv sale hiv patent expir car-t/pipelin drive risk-reward
less rapid eros hcv franchis strong pipelin realiz drive bull
case hiv product revenu reach hcv busi gener
sale sale yescarta filgotinib
gilead respect
rapid hcv eros lower pipelin success bull case hiv
product revenu reach hcv busi gener sale
sale yescarta filgotinib
gilead respect
stabl hiv revenu quick hcv busi eros minim pipelin
success hiv product revenu hcv busi gener
sale littl pipelin valu
equal-weight gilead believ
offer signific absolut
upsid near-term catalyst
term upsid rel gilead
signific return capit share
repurchas low forward price-to-earnings multipl
offer downsid protect
believ hcv peak us
continu declin modestli
howev believ cash flow gener
robust
hiv gilead done good job
switch nave patient new
stribild complera genvoya
truvada/atripla still hold market
right mean signific number
still need switch howev given time
solid taf switch data believ
least half market switch
car-t gilead acquisit kite provid
potenti renew long term revenu
main driver hiv franchis
hcv franchis car-t franchis
pipelin capit deploy repres
key driver
updat agreement galapago
entitl gilead commerci right
outsid europ jak inhibitor filgotinib
may provid near-term upsid
approv varieti inflammatori
risk achiev price
unexpect competit hiv
rapid hcv eros
appreci consensu
failur car-t achiev signific
market penetr failur meaning
signific delay regulatori
progress jak inhibitor filgotinib
darzalex ofatumumab label expans studi coupl matur mid-lat
darzalex ofatumumab label expans studi coupl matur mid-lat
pt deriv dcf use discount
rate termin growth rate revenu driver model
darzalex late-stag partner product ofatumumab
teprotumumab well earli stage proprietari compound
upsid darzalex uptak ofatumumab success ms greater risk-adjust
valu proprietari pipelin assum peak sale darzalex
ofatumumab peak sale pipelin peak sale
continu robust darzalex uptak ofatumumab success ms risk-
adjust valu proprietari pipelin assum peak sale
darzalex ofatumumab peak sale pipelin peak sale
assum blend probabl success
darzalex royalti valu bear case assum darzalex royalti
burden invest pipelin matur assum
greater competit out-year biosimilar cell therapi mm
base case
overweight thesi base
signific upsid skew risk/reward
proprietari pipelin given believ
darzalex royalti plu late-stag
partner pipelin alon account
current valuat genmab
believ darzalex royalti worth
coupl
late-stag pipelin ofatumumab ms
teprotumumab believ
ofatumumab teprotumumab could
believ earli mid-stag
proprietari pipelin under-valued
consensu repres compel
risk/reward valu proprietari pipelin
base case
bull case valuat
ofatumumab label expans ms
asclepio ii
teprotumumab approv
variou proprietari partner product
initi clinic readout
pivot phii data innovatv
tisotumab vedotin cervic cancer earli
risk achiev price
meet consensu expect
ofatumumab could fail late-stag trial
early-stag proprietari asset could fail
clinic success market penetr voxelotor previous drive
clinic success market penetr voxelotor previous drive
peak penetr voxelotor assum voxelotor demonstr
abil modifi lt marker scd pain sickl crise thrombot event
new standard care assum limit competit gene therapi
peak penetr voxelotor assum clinic success voxelotor
compar success gene therapi voxelotor gene therapi split
voxelotor fail case assum residu cash valu
market signific unmet medic
need voxelotor oral dose potenti
diseas modifi therapi posit well
compet market new therapi
decad market share suggest
us peak sale potenti
earli voxelotor data compel initi
data demonstr reduct sickl
cell improv red blood cell
marker hemoglobin reticulocyt ldh
believ data could translat
clinic outcom includ reduct
sickl crise pain thrombot event
market assumpt leav room
competit current model
peak penetr hbss leav room
gene therapi believ oral dose
could prefer gene therapi could offer
cur therapi could
prefer patient
regulatori progress potenti
commerci launch voxelotor
risk achiev price
regulatori setback failur voxelotor
greater success competitor therapi
gene therapi
epidiolex ramp drive gw share
epidiolex ramp drive gw share
pt deriv dcf use discount rate
termin growth rate beyond valu
program cannabinoid base therapi rare neurolog
epidiolex exce expect drug ramp well label indic
dravet lenox-gastaut strong label use
epidiolex ramp slower expect assum drug ramp well
label indic less steepli anticip off-label use minim
gw market leader medic
applic cannabis-rel intervent
sativex approv eu epidiolex
approv fda
transfer schedul
june food drug
cannabidiol cbd oral solut
treatment seizur two rare sever
form epilepsi lennox-gastaut syndrom
dravet syndrom posit phiii data
could lead tuber sclerosi complex
ad label
believ epidiolex would wide use
treatment refractori epilepsi
on-label off-label
sale ramp epidiolex primari
driver share valu
risk achiev price
gwph stock volatil stock
influenc heavili quarterli
epidiolex sale perform well
payer impos signific restrict
physician hesit prescrib
gwph adr british base
cost expens
sale
interest incom
equival
trade receiv asset
properti equip net
trade payabl
oblig financ leas
trade payabl
oblig financ leas
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
interest incom
depreci properti plant equip
impair properti plant equip
revers impair properti plant equip
amort intang asset
increas provis inventori
decreas defer signatur fee
loss dispos properti plant equip
research develop tax credit receiv
decreas /increas allow doubt debt
chang oper asset liabil
trade receiv asset
trade payabl defer revenu
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas intang asset
proce sale properti plant equip
net use invest activ
flow financ activ
proce exercis share option
proce new equiti issu
expens new equiti issu
proce warrant exercis
underwrit contribut toward expens new equiti issu
repay fit fund
proce financ leas
repay oblig financ leas
effect foreign exchang rate chang cash cash equival
chang equival
equival begin year
equival end year
pt base dcf use discount rate project free
cash flow base termin valu
onward use termin growth rate project revenu
lead product candid tnbc muc
bull case assum achiev greater adopt ww peak risk
adjust sale assum commerci treatment line
mtnbc acceler adopt muc er cancer
base case assum launch mtnbc addit
revenu stream earlier line muc er larg enter
assign risk adjust use mtnbc ww risk adjust sale
bear case assum fail receiv approv indic
stock trade cash valu
equal-weight driven concern
around uncertainti approv timelin
requir follow
sidelin fda
continu believ efficaci
safeti data see signific
unmet need mtnbc believ approv
could see rapid adopt peak
believ obtain multipl
label expans increas asset total
address market studi front line
mtnbc muc breast cancer
remedi approv
phiii data random ascent
studi mtnbc treatment earlier line
data hormon breast cancer muc
risk achiev price
management fail correct cmc-relat issu
competit landscap target
therapeut mtnbc muc increas
failur achiev signific label
expans earlier line therapi
jakafi perform oncolog dermatolog pipelin readout drive
jakafi perform oncolog dermatolog pipelin readout drive
deriv price target discount cash flow analysi
factor explicit revenu project use
discount rate termin growth rate
jakafi sale surpass upper rang long-term guidanc clear
blockbust perform ruxolitinib cream strong contribut
early-stag pipelin jakafi sale peak total
revenu ruxolitinib cream gener peak sale
peak sale
jakafi sale midpoint long-term guidanc coupl strong
pipelin realiz jakafi sale manag long-term
guidanc peak total revenu approv
strong uptak ruxolitinib cream vitiligo atop dermat aggreg peak
sale aggreg peak sale early-
jakafi sale manag guidanc modest royalti revenu
minim pipelin success jakafi sale peak royalti revenu
jakafi ex-u olumi peak iclusig sale
aggreg peak pipelin revenu
jakafi base busi room
grow hold right jakafi
ruxolitinib ex-u right held
novarti jakafi sale
grown y/i
y/i forecast
continu growth jakafi
meaning contribut label
expans graft versu host diseas
gvhd forecast peak jakafi sale
roughli midpoint
manag long-term guidanc
prior jakafi patent expir
believ key area investor focu
ruxolitinib cream vitiligo
pemigatinib jakafi life cycl extens
effort first set phiii ruxolitinib cream
data expect near-term atop
dermat phiii vitiligo data expect
adjust sale ruxolitinib cream
jakafi life cycl extens effort
pemigatinib bladder cancer expect
also await detail data
well updat management
progress on-going phiii gravitas-
program itacitinib chronic gvhd
factor grow jakafi sale base
strong contribut late-stag
pipelin result find current
risk/reward valuat balanc
phiii data jakafi gvhd
phiii data ruxolitinib cream atop
data pemigatinib bladder cancer
tumor agnost program
addit detail jakafi life cycl
risk achiev price
 jakafi sale perform
poor phiii result ruxolitinib cream
either due outright safeti and/or efficaci
failur due result clinic
failur and/or minim success earlier-
mileston contract revenu
cost expens
product revenu incl definite-liv intang amort
chang fair valu acquisition-rel conting consider
total cost expens
incom loss oper
unreal loss long-term invest
expens relat senior note convers
incom loss provis incom tax
provis incom tax
cash equival
prepaid expens current asset
restrict cash invest
properti equip net
accru current liabil
accumul comprehens incom
total liabil stockhold equiti
flow oper activ
in-process research develop
expens relat senior note convers
unreal loss long-term invest
chang fair valu acquisition-rel conting consider
chang oper asset liabil
prepaid expens asset
accru liabil
net cash provid use oper activ
flow invest activ
acquisit busi net cash acquir
purchas long-term invest
purchas market secur
sale matur market secur
net cash use invest activ
flow financ activ
proce issuanc common stock stock plan
proce issuanc common stock net
paid connect senior note convers
payment conting consider
net cash provid financ activ
effect exchang rate cash cash equival restrict cash invest
net increas cash cash equival restrict cash invest
cash equival restrict cash invest begin period
cash equival restrict cash invest end period
penetr durat ali therapi key valuat driver
penetr durat ali therapi key valuat driver
pt deriv dcf use discount rate
termin growth rate revenu driver model ali
market penetr us japan refractori frontlin
mainten treatment ntm
ali launch japan achiev
penetr respect refractori ntm popul major
patient take form mainten treatment also forecast low
doubl digit penetr frontlin popul us japan peak sale
respect
follow ali launch drug launch japan
reach penetr respect refractori ntm
popul less patient take mainten treatment start
year post launch assum modest frontlin penetr us japan peak
sale respect
ali achiev weak penetr japan
overweight insm given robust
data ali refractori induc ntm
patient derisk approv also provid
modest assumpt chronic dose
opportun note current data argu
investig label
geograph expans japan provid
addit lever see substanti
foreign sale larger ntm popul
prioriti review fda advisori
prepar japan file pmda
follow-up data long-term extens
convert studi full data
risk achiev price
failur reach market restrict
label target small portion
poor long term durabl driven
dropout safeti signal less differenti
standard treatment
delay life cycl manag studi
need obtain robust mainten
breo anoro success drive risk reward
breo anoro success drive risk reward
pt deriv dcf assum discount rate
breo anoro captur signific share market bull case
assum breo anoro characterist qd dose breo lack
ic anoro drive major share copd asthma
prescript given sluggish launch drug comfort
physician approv laba/icss see scenario unlik
model peak ww sale breo anoro
trelegi
breo anoro sluggish launch case assum breo
anoro gain modest share copd/asthma prescript model peak ww
sale breo anoro trelegi
breo anoro falter commerci bear case assum breo anoro
fail gain commerci traction model ww sale breo
anoro trelegi
underweight see limit
upsid valuat impli
potenti gsk consolid royalti
interest breo/anoro
launch breo anoro
sluggish far
breo qd dose potenti complianc
advantag howev top-line result
breo phiii trial suggest profil similar
patient switch approv laba/icss
compet least initi
laba/ class mean growth anoro
expect maba/tripl combo
cannib sale breo anoro
patient need come laba/
lama/laba take one drug
key driver model includ
royalti breo launch anoro
launch trelegi approv
risk achiev price
breo and/or anoro may sell better
compani may potenti
busi develop transact may
spinraza grow focu shift tegsedi
spinraza grow focu shift tegsedi
pt deriv dcf use discount rate
termin growth rate beyond valu ioni advanc
driven revenu upsid across lead pipelin drug assum spinraza
maintain rapid growth thrombocytopenia concern physician
patient allow tegsedi achiev stronger growth appli modest
pipelin valu drug includ ionis-fxirx ionis-apociii-lrx ionis-
apo -lrx ionis-httrx
spinraza still driver despit tegsedi approv assum spinraza
primari product revenu driver tegsedi sale grow launch limit
appli modest pipelin valu drug includ ionis-fxirx ionis-
apociii-lrx ionis-apo -lrx ionis-httrx
ioni unabl launch addit product base case scenario assum
spinraza sale fall short expect commerci challeng
emerg respect platform pipelin drug
antisens may promis drug
develop platform underweight
ioni believ safeti toler
concern like remain overhang
tegsedi launch underway expect
thrombocytopenia concern weekli
blood monitor like affect sale
see waylivra opportun
limit without clear path us market
spinraza blockbust treatment
type sma develop candid
like increas focu late stage
asset matur pipelin
antisens may promis drug
develop platform underweight
ioni believ safeti toler
concern like remain overhang
tegsedi launch underway expect
thrombocytopenia concern weekli
blood monitor like affect sale
see waylivra opportun
limit without clear path us market
spinraza blockbust treatment
type sma develop candid
like increas focu late stage
asset matur pipelin
risk achiev price
news flow regard either success
failur ioni pipelin could lead
swing share valu
data ioni pipelin alter
efficaci and/or safeti profil
clinic data competit program
alter dynam market ioni
current pursu
licens royalti revenu
cost expens
product revenues/royalti
net incom loss attribut akcea
net incom ioni
non-gaap net incom ioni
cash equival
invest equiti secur regulu therapeut inc
prepaid expens current asset
properti equip net
current portion long-term oblig
defer revenu net current portion
accumul comprehens incom
non-controlling interest akcea
total liabil sharehold equiti
adjust reconcil net loss net cash use oper activ
depreci amort
chang oper asset liabil
pre-paid expens asset
accru expens
net cash provid use oper activ
purchas properti plant equip
purchas market secur
sale matur market secur
net cash use invest activ
proce exercis stock option equiti
proce issuanc common stock
proce issuanc debt
net cash provid financ activ
chang cash cash equival
cash equival begin year
cash equival end year
market secur end year
equal-weight ironwood
expect linzess growth like stabil
multipl quarter
ration post expect spin
cyclerion push ironwood
deeper profit
key revenu driver model
use wacc termin growth rate
linzess becom domin player ib cic market linzess
prefer treatment ib cic domin prescript
product take greater share over-the-counter therapi push past
linzess remain steadi grower linzess gradual grow share ib cic
market beat brand player make headway
expens over-the-counter therapi net sale push past
linzess slow ibs-c cic market slow tough competit take share
risk achiev price
enabl upside/downsid versu
one compani pipelin drug could
achiev superior data lead us
increas expect regard
ration exceeds/fal short
expect lead upside/downsid
million per share basi indic
commerci cost expens
net profit loss sale linzess
ironwood share net profit loss
revenu
revenu
interest expens
interest invest incom
provis incom tax
net incom loss disc oper
million per share basi indic
cash equival
prepaid expens current asset
properti equip net
accru research develop cost
current portion long-term debt
current portion capit leas oblig
long-term liabil discont oper
accumul comprehens incom
total liabil stockhold equiti
million per share basi indic
incom loss discontinu oper
incom loss continu oper
depreci amort
loss gain dispos properti equip
impair loss long-liv asset
remeasur forward purchas contract
write-down inventori net realiz valu
loss facil subleas
accret discount premium invest secur
chang fair valu note hedg warrant
chang fair valu convert note hedg
chang oper asset liabil
chang inventori
prepaid expens current asset
account payabl accru expens
accru research develop cost
net cash use oper activ disc op
net cash use oper activ
purchas available-for-sal secur
sale matur available-for-sal secur
purchas ppe
proce sale properti equip subsidiari
proce sale subsidiari
net cash use invest activ
proce issuanc prefer stock net issuanc cost
proce share issuanc
proce exercis stock option stock purchas plan issuanc common
proce sale noncotrol interest subsidiari
tax benefit stock option
disburs repurchas common stock
proce issuanc note payabl
proce issuanc note hedg warrant
purchas convert note hedg
associ issuanc note payabl
payment borrow capit leas oblig
princip payment debt
net cash provid financ activ
increas cash cash equival
equival begin year
equival end year
data ucd program drive risk/reward
data ucd program drive risk/reward
pt deriv dcf use discount
rate termin growth rate revenu driver model
ucd
greater diagnosi rate larger set address patient ucd
vs base case ucd program gener peak risk-
adjust global sale respect assum
kaleido program approv overt minim patient appli
risk adjust ucd program respect
ucd program approv therapeut receiv signific
patient uptak ucd program gener peak risk-adjust
global sale respect uptak drive
bulk revenu due greater share higher price compar eu
assum kaleido program approv overt
popul appli risk adjust ucd
kaleido pipelin fail ucd program fail kaleido unabl
commerci mmt therapi assum share trade cash
value-per-share case
overweight kaleido thesi
base success commerci
mmt product treatment urea
cycl disord ucd hepat
kaleido take differenti approach
toward leverag gut microbiom
develop synthet analyt
capabl enabl kaleido gener
product candid rapidli kaleido
test mmt candid human non-ind
studi mmt complex carbohydr
molecul relat gra
gener recogn compound
allow kaleido progress directli
late-stag studi ind set-
may facilit speed market
abil progress product candid
strong proof-of-concept human
non-ind studi healthi
toler profil abil reduc
achiev statist signific base
earli yet encourag result
believ could lead posit result
clinic studi patient could progress
becom viabl therapeut ucd
ucd kaleido second lead
program posit top line
data recent report
addit program also plan
infect caus multi-drug resist
mdr pathogen cardiometabol liver
diseas i/o program
current earli believ could
becom futur pipelin driver data
lead ucd program prove
data phii studi ucd
ind
risk achiev price
poor phii data ucd patient
make investor question viabil
platform
neg data microbiom
compani weigh share
regulatori chang compromis
kaleido abil conduct non-ind studi
human could lengthen time
market push product revenu
futur
durabl data wet age-rel macular degener drive risk/reward
durabl data wet age-rel macular degener
pt deriv dcf use
discount rate revenu driver model kodiak lead anti-
vegf candid retin diseas
commerci multipl retin diseas strong uptak
commerci wet diabet eye diseas peak
penetr probabl success po total risk-adjust
revenu grow
commerci limit set retin diseas modest
uptak commerci wet peak
penetr probabl success po total risk-adjust revenu
grow peak
fail kodiak unabl develop trade cash
overweight thesi base
success commerci
sever compani commerci
anti-vegf therapi treatment
retin diseas burden monthli
bimonthli treatment reduc long
design extend therapeut
durabl compar current therapi
preclin data well-establish rabbit
model demonstr extend durabl
clean safeti profil
initi clinic data direct phib
phii interim analysi demonstr
demonstr efficaci durabl
wet diabet eye diseas
multipl studi begin
risk achiev price
investor question valu
increas toxic advanc patient
posit data competitor could weigh
market share especi
competitor data arriv prior pivot trial
margituximab posit updat proprietari dart bispecif platform
posit updat proprietari dart bispecif platform
advanc therapeut program
better uptak margituximab enoblituzumab bull scenario assum
sale treatment breast gastric cancer scenario also
assum enoblituzumab achiev success trial launch
treatment multipl solid tumor includ pipelin valu potenti
margetuximab peak margetuximab struggl achiev
modest success refractori breast cancer patient revenu
enoblituzumab includ pipelin valu potenti dart platform
failur commerci proprietari partner program macrogen
enoblituzumab gener product relat revenu includ pipelin valu
underweight macrogen though
margetuximab could approv base
inabl differenti os lower
expect respect
target enoblituzumab think could
offer greatest util combin
checkpoint inhibitor would like
see data increas
car-t like efficaci treatment cancer
manufactur packag
dart broadli applic
implement beyond oncolog effort
underway treat autoimmun
infecti diseas dart could effect
safeti toler issu could
present challeng though believ
broad bispecif antibodi platform
substanti potenti data point
mix would like see
improv data gain confid
clinic data dart bispecif
antibodi beyond
posit updat margetuximab head
bla file commerci launch would
bolster downsid support valuat
clinic updat includ
risk achiev price
margetuximab util could greater
expect
posit clinic data pipelin
stock appreci
revenu collabor agreement
revenu govern agreement
cost expens
product revenues/royalti
equival
prepaid expens current asset
properti equip net
defer revenu net current portion
total liabil sharehold equiti
adjust reconcil net loss net cash use oper activ
chang oper asset liabil
pre-paid expens asset
accru expens
net cash provid use oper activ
purchas properti plant equip
purchas market secur
sale matur market secur
payment asset acquisit
net cash use invest activ
proce exercis stock option equiti
proce issuanc common stock
net cash provid financ activ
chang cash cash equival
cash equival begin year
cash equival end year
market secur end year
deriv pt dcf base forecast
mrna base product candid use
discount rate termin growth rate
strong share pipelin program bull case valu
program base case well oncolog relaxin heart
failur fabri program risk adjust vari product
launch begin gener sale
flow flow
success pipelin program base case valu rsv
cmv hmpv pcv kra cancer vaccin program vegf-a
rare diseas program mma pa pku risk adjust vari
product launch begin gener sale
flow
flow
product candid face technology/clinical/regulatori failur
therefor gener revenu share trade cash value-per-share
overweight moderna compani
taken industri approach
develop mrna base therapeut
rapidli gener broad pipelin
program candid enter
mrna drug develop platform
diversifi scalabl compar
competitor mrna space
valid broad partnership
merck astrazeneca
signal gener preclin
earli clinic studi date indic
mrna therapeut activ
across wide varieti modal
indic rang prophylact
cancer vaccin rare diseas believ
mani program repres
abl screen product
candid rapidli due digit
manufactur capabl compani
plan progress five new product
candid clinic everi year
coupl initi proof-of-concept data
area enzym replac
disord would valid key area
approach allow signific
increas pipelin probabl success
addit earli clinic stage data
intratumor i/o local regen
therapeut modal
expect
nomin addit drug candid
risk achiev price
initi data platform
beli investor expect caus
investor write-off subsequ readout
delay abil gener
stronger expect competitor data
mavacamten drive risk/reward
mavacamten drive risk/reward
pt deriv discount cash flow analysi assum
discount rate termin growth rate assum peak us
market share ohcm nhcm dcm
adjust use probabl success po ohcm
po nhcm po dcm
higher po pipelin product assum higher po dcm
ohcm nhcm follow posit data readout
sale estim base conserv market share risk-adjust
base case assumpt describ price target methodolog
precis medicin platform fail unabl advanc product
candid trade cash value-per-share
overweight myokardia
well-defin subgroup unmet medic
need potenti grow beyond
promis phase data
gener lead asset mavacamten
show reduct left ventricular outflow
tract lvot gradient week
provid opportun upsid
enter clinic advanc
mavacamten regulatori updat nhcm
ohcm
full phase data dcm
risk achiev price
poor efficaci concern safeti data
explorer- hcm lower
probabl success ohcm
concern safeti data
prevent advanc
pt deriv dcf use discount rate
termin growth rate beyond valu nabriva antibiot
lefamulin achiev strong ramp inpati outpati set lefamulin
achiev peak sale contepo reach sale
expect gener might enter market
lefamulin achiev modest share iv use lead oral use discharg set
risk adjust lefamulin sale expect reach
contepo approach risk adjust sale
stock valu cash
lefamulin novel mechan action
provid need option cabp nabriva
lefamulin first-in-class system
pleuromutilin develop oral iv
use treat community-acquir bacteri
pneumonia cabp lefamulin cabp
target spectrum activ novel
mechan action resist seen
date provid import altern
option treatment cabp
expect gradual commerci adopt
lefamulin sale driven use
inpati set nabriva initi
account said repres
opportun drug
launch rep meant cover
target account gain
formulari access key highli
contepo anoth first-in class antibiot
us contepo first-in-class epoxid
 could potenti approv
cuti although opportun somewhat
key valu driver commerci
ramp lefamulin contepo
risk achiev price
contepo regulatori process could
lefamulin and/or contepo sale fail
potenti addit dilut financ
research premium grant revenu
cost expens
product revenues/royalti
oper expens
cash equival
prepaid expens current asset
properti equip net
accumul comprehens incom loss
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
non-cash incom net
chang oper asset liabil
accru expens liabil
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas term deposit
proce sale available-for-sal secur
transact
net use invest activ
flow financ activ
proce exercis stock option equiti
proce issuanc common stock
proce lt debt
effect fx translat
chang equival
equival begin year
equival end year
market secur end year
acquisit neon close
announc
acquisit close
risk achiev price
key risk acquisit biontech
close close significantli later
biontech acquisit neon drive risk/reward
biontech acquisit neon drive risk/reward
price target base announc acquisit valu
premium deal valu
premium deal valu
competit bid lead increas eventu acquisit price
acquisit close announc
acquisit close ntgn trade slight
premium cash value-per-share base investor expect continu
strateg interest neon
revenu
research develop
gener administr
income/ loss oper
accret redeem convert prefer stock redempt valu
net incom loss attribut common stock
cash equival
prepaid expens current asset
properti equip net
total liabil stockhold equiti
adjust reconcil net loss net cash use oper activ
depreci amort
net amort premium discount market secur
gains-to-loss sale properti equip
chang oper asset liabil
prepaid expens current asset
accru expens current liabil
net cash use oper activ
purchas market secur
sale matur market secur
purchas properti equip
proce sale properti equip
net cash use invest activ
proce issuanc seri
proce issuanc seri
proce exercis stock option
repurchas unvest restrict common stock
payment initi public offer cost
proce common stock offer
net cash provid financ activ
net decreas increas cash cash equival
cash equival begin period
cash equival end period
pt deriv dcf use discount
rate assum peak us market share td also model
peak us market share opicapon parkinson translat
ingrezza sale growth beat expect assum peak market share
vy-aadc abl reach market late
unadjust us ingrezza sale td base case assumpt
detail price target methodolog
slower growth td sale bear case assum lower peak us market
share ingrezza td translat peak sale
addit assum vy-aadc unsuccess reach market
overweight thesi driven ingrezza
even though question
whether growth slow think
possibl achiev peak sale
partnership voyag offer
exposur larg market earlier
full phase data adult
potenti approv orilissa uterin
potenti approv opicapon
risk achiev price
ingrezza sale growth td may continu
deceler
vy-aadc pivot studi enrol
expect safeti concern aris
pt deriv discount cash flow analysi assum
discount rate termin growth valu assum peak
impli us market share
nsclc adjust use probabl success po
higher po assum higher po peak share follow posit
base case assumpt describ price target methodolog
immunotherapi platform fail unabl advanc product
candid trade cash value-per-share
overweight nextcur
defin subgroup unmet medic need
potenti expand beyond
sinc express
overlap tumor tumor
respond therapi
phase data provid evid
addit program pipelin
candid find-io platform
provid opportun upsid enter
clinic advanc develop
ind solid tumor
phase proof-of-concept data
phase proof-of-mechan data
phase proof-of-concept data
risk achiev price
poor efficaci and/or safeti data lead
product candid lower po
lack advanc early-stag pipelin
andexxa becom standard care bleed andexxa gener global
peak sale forecast period ex-u
modest uptak andexxa andexxa gener global peak sale
forecast period ex-u
andexxa achiev base case peak sale assum andexxa
slow ramp modest penetr gener global sale
remain equal-weight base key
unknown risk associ launch
andexxa particularli given unforeseen
commerci pressur observ
await addit formulari updat
clariti launch metric
need physician support
factor xa antidot consider bleed
signific potenti devast
complic anticoagul
revenu driver model
launch perform andexxa
us eu row
risk achiev price
andexxa launch could inflect
near-term drastic anticip
either estim
million except per-shar data
collabor licens revenu
interest incom net
net incom portola non-gaap
million
equival
account interest receiv
prepaid expens current asset
properti equip net
accru liabil
current portion long-term debt
total liabil sharehold equiti
million
amort premium invest secur
chang reserv uncertain tax posit
issuanc convert prefer stock licens
loss dispos leasehold improv
reevalu prefer stock warrant liabil
chang asset liabil
account interest receiv
pre-paid current long-term asset
accru compens employe benefit
accru liabil
net cash provid use oper activ
purchas properti plant equip
increas restrict
purchas intang asset
purchas short-term invest
proce sale short-term invest
proce matur short-term invest
net cash use invest activ
repay debt
proce issuanc common stock
dividend non-controlling interest srx cardio
proce long-term note payabl net
proce long-term oblig collabor
repurchas unvest common stock
proce issuanc convert prefer stock
proce exercis warrant
net cash provid financ activ
chang due restat
chang equival
equival begin year
equival end year
market secur end year
pt deriv discount cash flow analysi assum
discount rate termin growth valu assum peak us
market share neuronopath gaucher diseas ngd
parkinson diseas mutat pd-gba adjust
use probabl success po respect
higher po pd-gba assum higher po peak share posit
base case assumpt describ price target methodolog
gene therapi platform fail prevail unabl advanc product
candid trade cash value-per-share
overweight prevail compani
patient subpopul unmet medic
preclin data suggest
efficaci safe anim
glucocerebrosidas gcase increas
glycolipid accumul reduc motor
function improv -synuclein
accumul reduc
de-risk vector track
record safeti efficaci support
recent approv novartis/avexi
zolgensma infant sma type
provid opportun
upsid enter clinic
advanc develop
upcom catalyst
begin phase type gaucher
begin phase ftd
begin phase type gaucher
initi phase data type
biomark data
clinic readout
risk achiev price
poor efficaci and/or safeti data lead
product candid lower
lack advanc early-stag pipelin
program osteoporosi oncolog drive risk/reward
program osteoporosi oncolog drive risk/reward
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model tymlo pen abaloparatid patch
osteoporosi well elacestr breast cancer
market leadership growth osteoporosi limit pressur
forteo gener risk-adjust elacestr bull case assum
tymlo pen patch achiev acceler switch forteo user
minim impact gener ww peak sale
pen patch elacestr respect
competit uptak tymlo commerci long term market
transfer patch probabl success po elacestr
base case assum tymlo obtain competit formulari posit
also commerci patch ww sale tymlo
pen patch elacestr respect
loss treatment popul forteo gener poor commerci
patch elacestr fail bear case assum tymlo pen increasingli
pressur entri multipl forteo gener patch fail
substanti grow anabol market ww peak sale
pen patch respect
overweight radiu
encourag trajectori date
osteoporosi drug tymlo lead us believ
tymlo captur sizeabl portion
anabol market
tymlo abaloparatid patch could
differenti product osteoporosi
market current anticip launch
given top line data on-going
phiii studi expect
elacestr gener encourag
data date path forward remain
unclear management aim find partner
asset result assign molecul
likelihood success radiu
continu focu quarterli tymlo
time launch price potenti
enrol updat phiii studi
underway abaloparatid patch
risk achiev price
disappoint launch trajectori tymlo
track prescript data formulari
failur defend market share
gener includ inabl bring
patch market
inabl partner elacestr time
manner lead minim valu contribut
asset near-to-mid term
eylea dupix drive risk-reward
eylea dupix drive risk-reward
better dupix penetr atop dermat asthma assum
us eylea row eylea sarilumab us
sale us dupilumab sale
sarilumab me-too compar actemra strong dupix penetr
asthma atop dermat assum us eylea
row eylea us sarilumab sale
us dupilumab sale
sarilumab still me-too modest dupix launch eylea face
greater branded/biosimilar competit assum us eylea
row eylea us praluent modest row
praluent sale sarilumab us sale
dupilumab sale
equal-weight regeneron
investor heavili scrutin dupix
prescript data sinc launch atop
dermat ad april believ
consensu still factor substanti sale
dupix ad well asthma see
risk/reward skew slightli
posit given steadi launch ad
recent approv asthma emerg
pipelin i/o see littl room near-
dupix initi launch trajectori
dupix encourag ad see
dupix durabl asset asthma
current project dupix
oper profit across atop
dermat asthma
praluent factor watch
develop new trial proceed
sanofi/regeneron
 praluent inflect come quarter
kevzara sarilumab see kevzara
me-too forecast sale
main driver dupix dupilumab
eylea emerg i/o pipelin
risk achiev price
unexpect flatten dupix
dupilumab launch trajectori
disappoint uptak asthma
competit success wamd space
limit uptak i/o asset
success use
success use partner proprietari program drive
technolog partner proprietari program drive
pt deriv dcf use discount rate
termin growth rate beyond valu
proprietari partner gene therapi program
commerci proprietari partner program model
strong uptak indic proprietari program
hofh mp wet respect gener peak
sale partner program mp iiia sma partnership
ultragenyx dimens dmd gene therapi sale gener peak
royalti revenu
commerci proprietari partner program model
modest uptak indic proprietari program
hofh mp wet respect gener peak
sale partner program mp iiia sma partnership
ultragenyx dimens dmd gene therapi revenu gener peak
royalti revenu
failur commerci proprietari partner program
receiv royalti avexi gener product relat
revenu bear case consist cash value-per-share well valu
royalti novartis/avexi sma program eu
overweight
believ compani technolog
platform alreadi broadli licens
across gene therapi landscap provid
potenti transform method
safe effect deliv gene
present known target clear endpoint
reduct hofh reduct
gag accumul mp mp ii
arrang de-risk regenxbio
platform help reduc binari risk
face tradit gene therapi compani
success licens program use
vector deliveri method
reduc technic risk face proprietari
recent posit gene therapi data
help de-risk broader gene therapi
data/upd wet
hofh program
advanc
program mp mp ii respect
updat avexi sma program
technolog license
risk achiev price
pipelin failur partner proprietari
neg safeti efficaci data gene
therapi program develop
either technolog license gene
therapi compani use vector outsid
platform
pt deriv dcf use discount rate
termin growth rate beyond valu rhythm program
orphan genet disord obes
setmelanotid approv launch pomc null lepr defici
setmelanotid data bardet-biedl syndrom bb alstrm
suggest drug could exceed expect indic rais
confid combin phiii trial
setmelanotid like reach market pomc null lepr
defici data bardet-biedl syndrom largest valu driver
incorpor alstrm risk adjust estim peak sale
setmelanotid
setmelanotid fail reach market rhythm trade cash
compel efficaci setmelanotid
two ultra-orphan diseas may result
setmelanotid underway data
expect studi
success would enabl regulatori
bardet-biedl signific
opportun rhythm pursu bardet-biedl
syndrom alstrm syndrom
addit indic rhythm present
data indic suggest
setmelanotid could offer benefit
patient phiii trial examin
indic set begin later year
increas rate diagnosi upon launch
key challeng import lever
setmelanotid commerci success
view increas test diagnosi
rate genet disord obes
patient target ideal candid
setmelanotid therapi current
undiagnos anticip
avail therapeut target
increas test diagnosi rate
believ rhythm would need invest
meaning captur patient
realiz potenti market opportun
key valuat driver perceiv clinic
regulatori risk setmelanotid
syndrom pomc heterozyg obes
risk achiev price
fail clinic trial setmelanotid
rhythm unabl enrol pivot trial
orphan indic
potenti dilut financ
cost expens
product revenues/royalti
net incom loss continu oper
cumul dividend convert prefer share
net loss attribut common stockhold
cash equival
prepaid expens current asset
properti equip net
due relat parti
accru expens current liabil
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
due relat parti
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas short-term invest
matur short-term invest
net use invest activ
flow financ activ
proce issuanc common stock
net proce issuanc seri convert prefer stock
proce lt debt
proce exercis stock option equiti
effect fx translat
chang equival
equival begin year
equival end year
market secur end year
initi rct data diseas ind file drive risk/reward
initi rct data diseas ind file drive risk/reward
pt deriv dcf use discount
rate termin valu onward base
termin growth rate valuat assign credit rubiu rare
diseas oncolog platform
commerci rare diseas oncolog immunolog strong
uptak commerci rare diseas pku gout
homocystinuria oncolog nsclc immunolog pemphigu vulgari
probabl success po pku gout
homocystinuria nsclc pemphigu vulgari total risk-
adjust revenu grow primari
revenu contributor peak pku gout
commerci rare diseas oncolog modest uptak
commerci rare diseas pku gout homocystinuria
nsclc within oncolog pku assign po gout homocystinuria
valu po nsclc assign po pku
commerci product candid launch
total risk-adjust revenu grow
primari revenu contributor peak pku gout
red platform fail rubiu unabl develop rct product candid
trade cash value-per-share
overweight thesi base
broad safe potenti applic
rubiu red platform could gener
diseas oncolog immunolog
pose white blood cell therapi like car-
includ broader applic off-the-
shelf approach improv safeti
rapid scalabl manufactur
preclin data encourag
date particularli rare diseas
platform ind applic lead
product candid
phenylketonuria pku approv fda
key risk across rubiu rare
diseas program deliveri risk
believ posit initi data
patient would address investor concern
significantli derisk rare diseas
program includ refractori gout
initi phi/ii studi
interim data patient
subsequ ind file futur rct
product candid
poor safeti and/or efficaci data rtx-
would like caus investor question
rubiu abil gener effect
investor may subsequ question
valu red platform assign limit
valu rare diseas oncolog
short circul time would
impair commerci prospect
platform could lead limit efficaci
posit data competitor either
platform compani
weigh rubiu share especi
competitor data arriv prior meaning
dataset rubiu
brexanolon launch primari valuat
brexanolon launch primari valuat
brexanolon approv asset
global peak sale potenti
clear unmet need form basi
valuat clear upsid
derisk data mdd
potenti much broader profil
insomnia parkinson diseas addit
indic multi-billon dollar
pipelin broad continu offer
new drug extens effort target
gaba nmda
brexanolon launch steep trajectori provid
bulk valuat strong launch mdd bipolar
insomnia
brexanolon key near-term driver
howev form bulk
brexanolon launch provid bulk valuat
launch mdd bipolar insomnia
approv mdd bipolar insomnia
launch modest
neg safeti efficaci data
therapeut program
unexpect delay clinic
potenti intellectu properti
challeng could impact futur revenu
long-term prospect sarepta dmd franchis drive valu
long-term prospect sarepta dmd franchis
pt deriv dcf use discount rate
termin growth beyond valu sarepta dmd franchis
bull scenario assum exondi achiev rapid launch sale
taper peak penetr achiev also assum aggress sale
exon approv well signific updat gene therapi
base case scenario assum continu strength exondi well
eventu approv golodirsen camisersen risk-adjust
dmd gene therapi total revenu
assum lower peak penetr exondi approv golodirsen
modest sale approv camisersen downstream eros usag
includ revenu altern mutat
overweight thesi base
strong initi dmd genetherapi data
manag abil captur signific
market share dmd gene therapi
product gene therapi remain riski
believ initi data derisk program
provid signific upsid potenti
base busi exon skip drug
pipelin larg divers offer lgmd
potenti upsid driver
time market clinic success
risk achiev price
updat dmd gene therapi
program includ risk relat
manufactur on-going regulatori
failur secur addit regulatori
approv obtain reimburs could
data competitor compani could
either posit neg impact
sarepta posit dmd market
continu uptak adcetri matur mid/late-stag pipelin asset drive risk
continu uptak adcetri matur mid/late-stag pipelin asset drive risk
equal-weight thesi base
estim continu growth adcetri
treatment chl certain subtyp
nhl see key growth driver increas
uptak exist indic potenti
label expans growth earlier line
therapi
enfortumab vedotin current
evalu pivot phii clinic trial
 fda assign pdufa date
vedotin tucatinib potenti
take share metastat cervic
technolog
out-licens number compani
firm entitl mileston royalti
payment collabor base sale
util technolog product
readout adcetri label expans
frontlin hl
upcom fda decis enfortumab
vedotin patient advanc
upcom readout tucatinib
bc neoadjuv bc i-spi
pivot phii readout tisotumab vedotin
cervic cancer
risk achiev price
adcetri revenu estim may
neg impact delay approv
competit product may enter
market erod adcetri market share
enfortumab vedotin tisotumab vedotin
tucatinib initi base limit phi
pt deriv dcf use discount
rate termin growth rate revenu driver model
 adcetri sale eu/row adcetri royalti revenu
estim also includ risk-adjust sale estim partner
product enfortumab vedotin tisotumab vedotin addit
vedotin tucatinib penetr assum continu uptak adcetri
driven label expans model peak canada adcetri sale
peak ex-u royalti seattl genet
assum commerci enfortumab vedotin
peak revenu sourc also model pos-adjust sale
tucatinib profit share sale tisotumab
continu adcetri growth enfortumab vedotin commerci near
term eventu approv tisotumab vedotin tucatinib assum
continu uptak adcetri driven label expans model peak
canada adcetri sale peak ex-u royalti
seattl genet assum commerci
enfortumab vedotin peak revenu sourc
also model pos-adjust sale tucatinib profit
share sale tisotumab vedotin
slower anticip growth adcetri sale along weak enfortumab
vedotin tucatinib penetr tisotumab vedotin fail achiev
commerci model peak adcetri sale
peak ex-u adcetri sale model peak canada
enfortumab vedotin sale peak tucatinib sale
clinic data defici safeti and/or
efficaci may discov product
candid continu evalu
compani may fail achiev fda
approv label expans pipelin
success develop entinostat hr breast cancer drive risk/reward
success develop entinostat hr breast cancer drive risk/reward
assum entinostat achiev rapid uptak hr bc assum combin
hormon therapi hr breast cancer exce base case expect
assum modest uptak hr bc assum modest hr her- breast cancer
sale project risk adjust
assum entinostat fail achiev suffici clinic result hr
equal-weight syndax
develop class hdac entinostat
near-term compani stock
leverag outcom phiii
trial hr breast cancer although
menin-llr program intrigu
confid entinostat/checkpoint
inhibitor combin wane somewhat
howev could eventu path
forward inflam tumor nsclc
melanoma
stock valuat highli link
success phiii trial
risk achiev price
neg safeti efficaci data
therapeut program
unexpect challeng checkpoint
inhibitor i/o therapi gener
could dampen syndax opportun
potenti intellectu properti
challeng could impact futur revenu
cost expens
product revenues/royalti
incom loss attribut stockhold
net incom loss attribut common stockhold
equival
market secur cash
prepaid expens current asset
properti equip net
defer revenu net current portion
total liabil sharehold equiti
adjust reconcil net loss net cash use oper activ
chang oper asset liabil
pre-paid expens asset
accru expens
net cash provid use oper activ
purchas properti plant equip
purchas market secur
sale matur market secur
payment asset acquisit
net cash use invest activ
proce exercis stock option equiti
proce issuanc common stock
net cash provid financ activ
chang cash cash equival
cash equival begin year
restrict includ line item
cash equival end year
market secur end year
crysvita drive risk/reward
crysvita
pt deriv dcf use discount
rate model peak risk-adjust revenu addit
peak ww sale mepsevii crysvita
model peak unadjust ww sale
adjust
use probabl success po
posit data readout better-than-expect launch assum higher
po po follow subsequ
confirm posit data cohort cohort respect
support advanc program phase addit assum
better-than-expect launch lead greater peak market share
crysvita mepsevii
strong crysvita launch base case assumpt describ price
target methodolog
pipelin product fail bear case assum fail
approv call question mepsevii crysvita face
slower adopt us
overweight rate base
belief street undervalu
crysvita launch remain strong
potenti upsid greater adopt
adult famili
data promis
confid program
like ultragenyx third
compani continu deepen
diversifi pipelin new gene therapi
mrna candid
data phase cohort
patient
potenti approv lc-faod
data phase cohort
risk achiev price
crysvita mepsevii may face
commercial/reimburs challeng
achiev suffici patient adopt
data subsequ indic
pipelin candid may succeed
even data posit fda may
probabl success anti-ag market well osteoarthr knee
probabl success anti-ag market well osteoarthr knee
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model osteoarthr oa addit
success oa drive peak ww sale probabl
success coupl probabl success penetr anti-ag
market broadli
success oa drive peak ww sale probabl
success coupl probabl success penetr anti-ag
market broadli remain bull case
program fail valu compani cash
manag pioneer novel
biolog senesc cell
opportun deliv step-funct chang
treatment chronic diseas
preclin model support
impact sasp factor senesc
suggest benefit
remov senesc cell
oa offer proof-of-concept model
clear biomark clinic endpoint
follow-up long-term chronic data
addit ind file follow-up
product includ eye
risk achiev price
biolog approach
novel initi program fail falter
investor like heavili discount
competit space
privat
initi oa program may right
target test senesc cell snc
follow-up period dose period
medicin may long enough
kinet remov snc see
therapeut respons known
base case valuat deriv explicit forecast actr
boxr product discount termin growth rate
efficaci solid tumor modest success liquid tumor
progress nhl highli differenti data construct gener
peak risk-adjust sale solid tumor platform gener
peak sale across actr boxr platform
efficaci solid tumor minim contribut liquid tumor
progress nhl gener peak risk-adjust sale
solid tumor platform gener peak sale across actr
actr boxr product candid fail across solid liquid tumor actr
boxr product candid fail aggress cash burn continu
result share eventu trade low cash value-per-share
overweight unum base
view technolog could provid
robust therapeut window compar
especi solid tumor
believ recent realloc
resourc solid tumor platform
sensibl find progress boxr
believ umrx current valuat
level combin potenti cell
therapi solid tumor present attract
risk/reward profil head key solid
enrol safeti updat
trastuzumab solid tumor
initi efficaci data
studi
ind file late
risk achiev price
concern safeti signal
safeti updat expect
ind file delay beyond
abil financ broader
develop boxr platform solid
cost expens
product revenues/royalti
loss discontinu oper net tax
loss sale discontinu oper net tax
net loss comprehens loss
equival
prepaid expens current asset
properti equip net
defer revenu net current portion
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
pre-paid expens asset
accru expens liabil
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas market secur
sale matur market secur
net use invest activ
flow financ activ
proce exercis stock option equiti
proce issuanc common stock
chang equival
equival begin year
equival end year
market secur end year
triplet approv
triplet approv uptak life-cycl manag oper margin drive
uptak life-cycl manag oper margin drive
ww penetr across cf medicin life-cycl extens extend
franchis bull case assum higher penetr tripl
therapi het/min homozygot patient initi tripl data
replic phiii therapi launch ww sale
cf aatd us eu commerci success key
ww peak sale cf mainten key cf franchis life-cycl
extens base case assum penetr tripl
combin homozygot heterozygot risk-adjust peak ww
sale cf aatd
modest orkambi uptak bear case assum row us
penetr orkambi homozyg cf patient total peak ww sale
cf aatd therapi peak
overweight vertex believ
initi tripl data replic phiii
studi see vertex clear leader
cf therapi believ manag
potenti deliv ep
initi phi phii data tripl
het/min popul better
kalydeco-lin efficaci
homozyg popul thu includ
risk-adjust tripl combin revenu
base case
efficaci data aatd mice model
suggest efficaci corrector human
therefor model includ risk-
adjust revenu corrector
believ potenti
competit believ vertex
signific advantag posit
on-market doubl combin in-
share competitor long-
main driver vertex uptak
current therapi
orkambi/kalydeco/trikafta uptak in-
risk achiev price
combo penetr fall short
kalydeco sale fail meet
data competit exce
clinic trial nda file
inebilizumab nmosd drive risk/reward
inebilizumab nmosd drive risk/reward
pt deriv discount cash flow analysi assum
discount rate termin growth valu assum peak us
market share nmosd adjust use probabl
inebilizumab approv nmosd faster uptak assum
po higher peak share quicker ramp launch also assum higher
po pipelin program mg sjgren kidney
base case assumpt describ price target methodolog
fda request addit data result delay approv assum
lower po inebilizumab nmo assum slower uptak
overweight viela compani
develop treatment autoimmun
inebilizumab clinic de-risk
nmosd follow posit phase data
think like approv mid-
believ inebilizumab like one
favor treatment front-lin
addit
indic inebilizumab provid
opportun upsid
upcom catalyst
begin phase studi inebilizumab
interim data phase studi
cutan lupu erythmetatosu
potenti approv inebilizumab
submit ind initi pivot trial mg
submit ind initi phase trial
risk achiev price
fda may approv inebilizumab
launch inebilizumab nmosd may
slower expect due intens
competit soliri satralizumab
lack advanc pipelin
vy-aadc parkinson drive risk/reward
vy-aadc parkinson drive risk/reward
pt deriv dcf use discount
rate model unadjust ww vy-aadc revenu
voyag receiv profit share us low- high-
teen royalti eu sale risk-adjust use po vy-
huntington model peak unadjust ww sale
adjust use po
optimist view vy-aadc scenario assum po
follow strong long-term data greater market share vy-aadc us
eu
vy-aadc us launch base case assumpt describ
price target methodolog
gene therapi platform fail bear case assum voyag unabl
advanc product candid trade cash value-per-share
equal-weight rate base limit
clinic catalyst
major valuat driven
vy-aadc parkinson
file ind huntington
vy-aadc phase data
vy-aadc phase data
risk achiev price
enrol faster expect addit vy-
aadc data increas investor confid
program expect
earli stage candid advanc
clinic vy-aadc pivot studi
enrol expect safeti concern aris
longer term data reflect strong
durabl respons
pt deriv dcf use discount rate
glepaglutid dasiglucagon demonstr superior profil product
differenti sb hypoglycemia respect lead acceler
uptak versu current standard care
dasiglucagon glepaglutid competit pipelin asset
approv view competit standard care
late state pipelin falter dasiglucagon glepaglutid fail reach
dasiglucagon glepaglutid driver
dasiglucagon glepaglutid driver
strong pipelin support ow rate
view zealand strong pipelin
led two therapi glepaglutid
dasiglucagon improv version
standard care drug
dasiglucagon could better offer
dasiglucagon rescu medic
sever hypoglycemia repres
conveni offer current market
glucagon like drive strong uptak
therapi approv potenti futur use
artifici pancrea system orphan
repres upsid estim
glepaglutid next-gen
could improv profil teduglutid
earlier featur short half
life requir complex multi-step
reconstitut process prior administr
glepaglutid enhanc stabil
extend half life allow drug
glepaglutid dasiglucagon success
risk achiev price
fail clinic trial pipelin candid
dasiglucagon glepaglutid
potenti need rais dilut equiti
dkk million
cost expens
product revenues/royalti
nsdq zeal dkk million
prepaid expens current asset
properti equip net
total liabil sharehold equiti
nsdq zeal dkk million
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
chang work capit
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas secur
purchas invest
transfer to/from restrict cash relat royalti bond
transfer restrict cash royalti bond interest payment
net use invest activ
flow financ activ
proce issuanc share relat exercis warrant
proce issuanc common stock
repay royalti bond
effect exchang rate
chang equival
equival begin year
equival end year
market secur end year
